eprintid: 11523
rev_number: 2
eprint_status: archive
userid: 1
dir: disk0/00/01/15/23
datestamp: 2023-11-10 03:26:02
lastmod: 2023-11-10 03:26:02
status_changed: 2023-11-10 01:15:28
type: article
metadata_visibility: show
creators_name: Chowdhury, M.R.
creators_name: Moshikur, R.M.
creators_name: Wakabayashi, R.
creators_name: Tahara, Y.
creators_name: Kamiya, N.
creators_name: Moniruzzaman, M.
creators_name: Goto, M.
title: In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations
ispublished: pub
keywords: paclitaxel; antineoplastic agent; cremophor; glycerol; ionic liquid; paclitaxel, allergic reaction; animal experiment; animal model; antineoplastic activity; area under the curve; Article; behavior change; biocompatibility; blood vessel permeability; cancer growth; cancer inhibition; cancer size; cell division; cell viability; complement activation; controlled study; drug delivery system; drug efficacy; drug elimination; drug formulation; drug retention; drug solubility; drug stability; female; follow up; high performance liquid chromatography; histamine release; hypersensitivity; in vitro study; in vivo study; mouse; nonhuman; particle size; priority journal; rate constant; survival time; animal; C57BL mouse; drug delivery system; drug hypersensitivity; intravenous drug administration; melanoma; skin tumor; tumor cell line, Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Hypersensitivity; Female; Glycerol; Ionic Liquids; Melanoma; Mice, Inbred C57BL; Paclitaxel; Skin Neoplasms
note: cited By 28
abstract: In order to prevent common hypersensitivity reactions to paclitaxel injections (Taxol), we previously reported an ionic liquid-mediated paclitaxel (IL-PTX)formulation with small particle size and narrow size distribution. The preliminary work showed high PTX solubility in the IL, and the formulation demonstrated similar antitumor activity to Taxol, while inducing a smaller hypersensitivity effect in in vitro cell experiments. In this study, the stability of the IL-PTX formulation was monitored by quantitative HPLC analysis, which showed that IL-PTX was more stable at 4 °C than at room temperature. The in vivo study showed that the IL-PTX formulation could be used in a therapeutic application as a biocompatible component of a drug delivery system. To assess the in-vivo biocompatibility, IL or IL-mediated formulations were administered intravenously by maintaining physiological buffered conditions (neutral pH and isotonic salt concentration). From in vivo pharmacokinetics data, the IL-PTX formulation was found to have a similar systemic circulation time and slower elimination rate compared to cremophor EL mediated paclitaxel (CrEL-PTX). Furthermore, in vivo antitumor and hypersensitivity experiments in C57BL/6 mice revealed that IL-PTX had similar antitumor activity to CrEL-PTX, but a significantly smaller hypersensitivity effect compared with CrEL-PTX. Therefore, the IL-mediated formulation has potential to be an effective and safe drug delivery system for PTX. © 2019 Elsevier B.V.
date: 2019
publisher: Elsevier B.V.
official_url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85065414856&doi=10.1016%2fj.ijpharm.2019.05.020&partnerID=40&md5=b60958bb8dae38009058c31b09a12caa
id_number: 10.1016/j.ijpharm.2019.05.020
full_text_status: none
publication: International Journal of Pharmaceutics
volume: 565
pagerange: 219-226
refereed: TRUE
issn: 03785173
citation:   Chowdhury, M.R. and Moshikur, R.M. and Wakabayashi, R. and Tahara, Y. and Kamiya, N. and Moniruzzaman, M. and Goto, M.  (2019) In vivo biocompatibility, pharmacokinetics, antitumor efficacy, and hypersensitivity evaluation of ionic liquid-mediated paclitaxel formulations.  International Journal of Pharmaceutics, 565.  pp. 219-226.  ISSN 03785173